The Federal Trade Commission’s amicus filing Monday in a Third Circuit pharmaceutical antitrust case shows where the commission has turned its efforts on fighting reverse-payment settlements after the U.S. Supreme Court’s ruling in FTC v. Actavis, a commissioner said in outlining her thoughts on such settlements.
FTC Commissioner Maureen K. Ohlhausen, who was speaking at an antitrust seminar at Dechert on Tuesday, said she thought the Supreme Court got it right in Actavis when it rejected last year both the FTC’s position that reverse-payment settlements were unlawful and the position taken by the U.S. Court of Appeals for the Eleventh Circuit that such settlements didn’t require antitrust scrutiny. The justices found the appropriate middle ground, Ohlhausen said.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
